Anti-CD3 Antibodies Enhance T-cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies targeting CD3 for cancer treatment are limited in their ability to effectively activate CD3+ T cells to enhance immune responses against cancerous tumors.
Innovation Solution
Development of anti-CD3 monoclonal antibodies with specific binding affinity and antigen-binding fragments that can activate CD3+ T cells, enhance T-cell proliferation, and reverse immunosuppressive functions, potentially used in combination with chemotherapeutic agents or as part of immunoconjugates for targeted cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies targeting CD3 are used for cancer treatment, then immune suppression is achieved, but T-cell activation and immune response enhancement are insufficient
Solution Approach 1:
The antibody is engineered to recognize specific epitopes on the CD3 complex (such as the CD3ε Fc region) with localized specificity, enabling differential effects: suppressing harmful immune responses while preserving or enhancing anti-tumor T-cell activation through selective epitope binding
Solution Approach 2:
The patent modifies antibody parameters including affinity (Kd values), specificity for different CD3 chains (γ, δ, ε), and binding kinetics to achieve optimal balance between immune suppression and T-cell activation, with antibodies showing Kd values in the 10^-9 to 10^-11 M range for enhanced efficacy
Data Source
AI summary
The applications provides the anti-CD3 monoclonal antibodies, antigen-binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to active CD3+ T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.